Both dupilumab and mepolizumab were originally approved for asthma but were subsequently studied in patients with COPD who continue to experience symptoms and moderate-to-severe exacerbations despite ...

Please provide your email address to receive an email when new articles are posted on . The FDA issued a warning in 2019 about serious breathing problems associated with gabapentinoids. The study ...

Synchrony Medical's LibAirty system for addressing mucus obstruction in COPD patients gained FDA clearance in July 2025.

Gabapentinoid use, namely gabapentin and pregabalin, was associated with increased risk for severe chronic obstructive pulmonary disease (COPD) exacerbation in patients with epilepsy, neuropathic pain ...

Gabapentinoid use in patients with chronic obstructive pulmonary disease (COPD) was associated with a higher risk for severe exacerbations, a population-based cohort study from Canada indicated. Among ...

Inhaled maintenance therapy is underused among hospitalized patients with COPD in China, even in those with frequent prior hospitalizations.

Please provide your email address to receive an email when new articles are posted on . Patients receiving dupilumab vs. placebo had a significantly lower risk for at least one severe exacerbation.

The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease (COPD), Sanofi and Regeneron announced on Friday. An injectable interleukin ...

Certain neighborhood characteristics, including higher poverty, more uninsured residents, and lower educational attainment, may lead to an increase in COPD-related emergency department visits and ...

Chronic obstructive pulmonary disease (COPD) is a group of diseases that affect the lungs. The disease makes it difficult to breath and progressively gets worse. About 15 million Americans have been ...